MNOV Medicinova Inc
Price (delayed)
$1.41
Market cap
$69.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.23
Enterprise value
$28.99M
MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S.
Highlights
The debt has contracted by 10% YoY and by 4.1% from the previous quarter
The company's revenue has shrunk by 100% YoY
Medicinova's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of MNOV
Market
Valuations
Earnings
Shares outstanding
49.05M
Market cap
$69.16M
Enterprise value
$28.99M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.32
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$12.68M
Net income
-$11.05M
EBIT
-$11.04M
EBITDA
-$10.85M
Free cash flow
-$10.64M
Per share
Balance sheet
Liquidity
EPS
-$0.23
EPS diluted
-$0.23
Free cash flow per share
-$0.22
Book value per share
$1.07
Revenue per share
$0
TBVPS
$0.94
Total assets
$55.88M
Total liabilities
$3.37M
Debt
$193,769
Equity
$52.5M
Working capital
$38.12M
Debt to equity
0
Current ratio
13.88
Quick ratio
13.64
Net debt/EBITDA
3.7
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-18.6%
Return on equity
-19.7%
Return on invested capital
-294.2%
Return on capital employed
-20.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MNOV stock price
How has the Medicinova stock price performed over time
Intraday
-2.76%
1 week
-4.08%
1 month
-14.02%
1 year
-5.37%
YTD
-32.86%
QTD
-3.42%
Financial performance
How have Medicinova's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.68M
Net income
-$11.05M
Gross margin
N/A
Net margin
N/A
The company's revenue has shrunk by 100% YoY
Medicinova's gross profit has shrunk by 100% YoY
MNOV's net income is down by 29% YoY and by 7% from the previous quarter
The operating income is down by 28% year-on-year and by 5% since the previous quarter
Growth
What is Medicinova's growth rate over time
Valuation
What is Medicinova stock price valuation
P/E
N/A
P/B
1.32
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
MNOV's EPS is down by 35% year-on-year and by 10% since the previous quarter
The P/B is 29% lower than the 5-year quarterly average of 1.9 and 16% lower than the last 4 quarters average of 1.6
The equity has declined by 16% year-on-year and by 4.7% since the previous quarter
The company's revenue has shrunk by 100% YoY
Efficiency
How efficient is Medicinova business performance
Medicinova's return on equity has decreased by 49% YoY and by 13% QoQ
The ROA fell by 49% YoY and by 12% QoQ
MNOV's ROIC is down by 23% YoY and by 3.4% QoQ
Dividends
What is MNOV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MNOV.
Financial health
How did Medicinova financials performed over time
MNOV's current ratio is down by 17% since the previous quarter and by 11% year-on-year
MNOV's total assets is down by 16% year-on-year and by 3.9% since the previous quarter
The debt is 100% less than the equity
The equity has declined by 16% year-on-year and by 4.7% since the previous quarter
The debt has contracted by 10% YoY and by 4.1% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.